Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in active polyarticular-course juvenile idiopathic arthritis (CHERISH)
NCT00988221Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2009
- Primary completion
- Nov 2011
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of tocilizumab in polyarticular juvenile idiopathic arthritis (4 arms), sponsored by Roche. Primary endpoint: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare. Started Nov 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
polyarticular juvenile idiopathic arthritis
Beyond the preview
Go deeper on NCT00988221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00988221.